Safety issues in MSC therapy

Mesenchymal Stromal Cells: Biology and Clinical Applications

Volumn , Issue , 2013, Pages 377-387

  Battiwalla, Minoo ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901362371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5711-4_20     Document Type: Chapter

References (50)

1. Tolar J, Nauta AJ, Osbom MJ, Panoskaltsis Mortaii A, McElmurry RT, Bell S et al (2007) Sarcoma derived from cultured mesenchymal stem cell. Stem Cells 25(2):371-379
2. Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J et al (2008) Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 68(11):4229-4238
3. Fehrer C, Lepperdinger G (2005) Mesenchymal stem cell aging. Exp Gerontol 40(12):926-930
4. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M (2008) Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 43(11): 1018-1023
5. Larson BL, Ylostalo J, Lee RH, Gregory C, Prockop DJ (2010) Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A 16(11):3385-3394
6. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG et al (2010) Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 12(5):576-578
7. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F (2008) Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15(10):730-738
8. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B et al (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4):e4992
9. Ishii G, Sangai T, Oda T, Aoyagi Y, Hasebe T, Kanomata N et al (2003) Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 309(1):232-240
10. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D et al (2004) Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 64(23):8492-8495
11. Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ (2010) Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 14(9):2292-2304
12. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J et al (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102(10):3837-3844
13. Yu JM, Jun ES, Bae YC, Jung JS (2008) Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 17(3):463-473
14. Kinnaird T, Stabile E, Burnett MS, Epstein SE (2004) Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 95(4):354-363
15. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S et al (2004) Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109(12):1543-1549
16. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K (2003) Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 75(1):204-209
17. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A (2004) Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92(1):47-56
18. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-563
19. Maestroni GJ, Hertens E, Galli P (1999) Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 55(4):663-667
20. Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M (2003) Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 75(3):248-255
21. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H et al (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11 (14): 1155-1164
22. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II et al (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203(5):1235-1247
23. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC (2008) The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10(7):657-667
24. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D (2006) Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 82(8):1060-1066
25. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM et al (2010) An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 28(6): 1107-1115
26. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829-834
27. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22(5):941-950
28. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture- expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving highdose chemotherapy. J Clin Oncol 18(2):307-316
29. Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS et al (2002) Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 118(4):1128-1131
30. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439-1441
31. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W et al (2001) Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 29(2):244-255
32. Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14(9):2519-2526
33. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F (2007) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21(2):304-310
34. Roorda BD, Elst A, Boer TG, Kamps WA, de Bont ES (2010) Mesenchymal stem cells contribute to tumor cell proliferation by direct cell-cell contact interactions. Cancer Invest 28(5):526-534
35. Kyriakou CA, Yong KL, Benjamin R, Pizzey A, Dogan A, Singh N et al (2006) Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med 8(3):253-264
36. Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R et al (2007) A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 21(10):2181-2191
37. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3):593-599
38. Behre G, Theurich S, Weber T, Christopeit M (2009) Reply to 'The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical study' by Ning et al. Leukemia 23(1):178; author reply 9-80
39. EU Regulations (2007) Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available from: http://eur-lex. europa.eu/LexUriServ/site/en/oj/2007/l_324/l_32420071210en01210137.pdf, Accessed November 2010
40. Halme DG, Kessler DA (2006) FDA regulation of stem-cell-based therapies. N Engl J Med 355(16):1730-1735
41. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K (2007) No alloanti- bodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92(9): 1208-1215
42. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X et al (2005) Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205(2):228-236
43. Le Blanc K, Samuelsson H, Lonnies L, Sundin M, Ringden O (2007) Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 84(8):1055-1059
44. Sundin M, Lindblom A, Orvell C, Barrett AJ, Sundberg B, Watz E et al (2008) Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. Biol Blood Marrow Transplant 14(10):1172-1179
45. Larson BL, Ylostalo J, Prockop DJ (2008) Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 26(1):193-201
46. von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, Hagglund H et al (2012) Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18(4):557-564
47. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD (2004) Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 363(9411):783-784
48. Chang MG, Tung L, Sekar RB, Chang CY, Cysyk J, Dong P et al (2006) Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 113(15):1832-1841
49. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54(24):2277-2286
50. Battiwalla M, Hematti P (2009) Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 11 (5): 503-515